Seattle Children's Hospital launches immunotherapy collaborative to expand clinical trial access at children's hospitals

Children's Hospitals
Seattle Children's, joined by Children's National Health System BC Children's Hospital and Children's Hospital of Los Angeles, started an international collaborative to expand patient access to cancer immunotherapy trials. (GeorgeRudy/Getty Images)

Four academic children's hospitals have joined forces to create a research collaborative that will make it easier for their patients to access immunotherapy clinical trials and for their researchers to find good candidates for therapies. 

Led by Seattle Children's, the new initiative called CureWorks will allow member hospitals to participate in clinical trials and share data and collective expertise with the goal of accelerating progress in developing novel cell therapies

Children's National Health System in Washington, D.C., Children's Hospital Los Angeles and BC Children's Hospital in Vancouver, British Columbia, are among the founding members.

Conference

13th Partnering with ACOS & IDNS Summit

This two-day summit taking place on June 10–11, 2019, offers a unique opportunity to have invaluable face-to-face time with key executives from various ACOs and IDNs from the entire nation – totaling over 3.5 million patients served in 2018. Exclusively at this summit, attendees are provided with inside information and data from case studies on how to structure an ACO/IDN pitch, allowing them to gain the tools to position their organization as a “strategic partner” to ACOs and IDNs, rather than a merely a “vendor.”

RELATED: How Connecticut Children's dramatically reduced pressure injuries

CureWorks will both facilitate the production of immunotherapy treatments and streamline the clinical trial enrollment and coordination process for member hospitals, officials said.   

"We believe a unified effort among leading children's hospitals is the best way to drive the discovery of new therapies for pediatric cancer," said Mike Jensen, M.D., executive director of CureWorks and director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute in a statement. "Our hope is that through this collaboration, we'll be able to more quickly develop treatments with fewer side effects, better readmission rates and, ultimately, enable more kids with cancer to grow up and realize their full potential.". 

Member hospitals will have the option to participate in clinical trials offered through CureWorks. Once trials are open at a member hospital site, immune cells will be collected from the patient and sent to a Seattle Children's facility where T-cells, or immune cells, will be reprogrammed to express the chimeric antigen receptor, or CAR protein, which artificially generates T-cells targeted to markers found on cancer cells to fight cancer.. 

The newly engineered cells will be shipped back to the patient's healthcare team for infusion. Officials said the cells will help more quickly create immunotherapy treatments and clinical trial enrollment and coordination. 

RELATED: Nemours Children’s Health System names Moss as new president and CEO

Suggested Articles

Vital, a digital health startup that developed a cloud-based, AI-powered software platform for emergency departments, has raised $5.2 million.

A wearable device that uses AI to remotely track and analyze vital signs while worn by patients at home has been cleared by the FDA.

A federal judge in Oregon Tuesday said he would grant a preliminary injunction to block the Trump administration’s Title X abortion rule.